6533b7d7fe1ef96bd1267aa2
RESEARCH PRODUCT
Galectin-3 in acute coronary syndrome
Luisa AgnelloGiulia BivonaChiara BelliaViviana BazanConcetta ScazzoneMarcello CiaccioBruna Lo Sassosubject
0301 basic medicinemedicine.medical_specialtyAcute coronary syndromeAcute coronary syndrome; AMI; Galectin-3; Heart failure; Myocardial infarction; Prognosis; Acute Coronary Syndrome; Atherosclerosis; Biomarkers; Galectin 3; Heart Failure; Humans; Myocardial Infarction; Prognosis; Evidence-Based Medicine; Clinical BiochemistryPrognosiGalectinsGalectin 3Clinical BiochemistryMyocardial InfarctionDisease030204 cardiovascular system & hematologyAMI03 medical and health sciences0302 clinical medicineFibrosismedicineHumansGalectin-3Myocardial infarctionIntensive care medicineHeart FailureEvidence-Based Medicinebiologybusiness.industryGold standardGeneral MedicineBlood ProteinsBiomarkermedicine.diseaseAtherosclerosisPrognosisTroponin030104 developmental biologyGalectin-3Heart failureAtherosclerosibiology.proteinAcute coronary syndromebusinessBiomarkersHumandescription
Acute coronary syndrome (ACS) is a very common cause of hospitalizations worldwide each year. In the past decades biomarkers have become an indispensable tool for diagnosis, risk stratification and prognosis of cardiovascular disease, including ACS. Despite Troponin is considered the gold standard in diagnosis of ACS, several molecules have been investigated to identify predictive biomarkers of prognosis. Among these, Gal-3 has emerged as a promising prognostic marker. It has a pivotal role in inflammation and fibrosis. Both experimental and clinical studies have shown Gal-3 is an independent predictor of all-cause mortality, cardiovascular death and occurrence of HF following ACS. This article reviews the literature data regarding the role of Galectin-3 in ACS setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |